In the present study, we discovered that pristimerin potently blocked NF-κB signaling and dramatically downregulated Bcr-Abl mRNA regardless of the mutational status of Bcr-Abl, inhibited growth and induced apoptosis in CML cells harboring wild-type Bcr-Abl or Bcr-Abl-T315I mutation. Here, NFKB1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.